<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60461">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02001935</url>
  </required_header>
  <id_info>
    <org_study_id>81302846</org_study_id>
    <nct_id>NCT02001935</nct_id>
  </id_info>
  <brief_title>Association Between CytochromeP4501A2 and CytochromeP4502E1 Gene Polymorphisms and Metabolism of Theophylline</brief_title>
  <official_title>Association Between CytochromeP4501A2(CYP1A2) and CytochromeP4502E1(CYP2E1) Gene Polymorphisms and Metabolism of Theophylline in a Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether common CYP1A2 and CYP2E1 gene polymorphisms
      effect metabolism of theophylline in chronic obstructive pulmonary disease patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Theophylline clearance</measure>
    <time_frame>Blood samples will be taken after receiving oral  thoephylline for 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Theophylline and it's metabolite(1,3-dimethyluric) blood concentration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>theophylline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>theophylline</intervention_name>
    <description>After oral theophylline 200mg per day for two weeks,bood sample  will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1</description>
    <arm_group_label>theophylline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-75 years,COPD patients, male or female;

          -  regularly visiting our hospital;

          -  taking a sustained-release preparation of theophylline continuously for at least 2
             weeks

        Exclusion Criteria:

          -  patients with renal or hepatic dysfunction;

          -  patients with congestive heart failure;

          -  patients with hypothyroidism or hyperthyroidism;

          -  patients currently taking drugs likely to affect theophylline metabolism or who had
             taken such drugs in the preceding week;

          -  patients with extreme obesity

          -  patients with very severe Chronic Obstructive Pulmonary Disease(COPD)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Liqing, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhujiang Hospital,Southern Medical Unversity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Liqing, Doctor</last_name>
    <phone>+86-02062783391</phone>
    <email>wliqing07@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhujiang Hospital,Southern Medical Universtiy</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Liqing, doctor</last_name>
      <phone>+86-02062783391</phone>
      <email>wliqing07@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Wang Liqing, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 28, 2013</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>theophylline</keyword>
  <keyword>CYP1A2</keyword>
  <keyword>CYP2E1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
